Cingulate Announces the Closing of a $12 Million Private Placement Priced At-the-Market Under Nasdaq Rules
MWN-AI** Summary
Cingulate Inc. (NASDAQ: CING), a Kansas City-based biopharmaceutical firm focused on developing next-generation ADHD treatments, has successfully closed a $12 million private investment in public equity (PIPE). The financing, led by Falcon Creek Capital Advisors, involves life science-focused institutional investors, confirming strong market interest in Cingulate's innovative strategy and technology. CEO Shane J. Schaffer emphasized the transaction's significance, mentioning its alignment with current market conditions and the participation of insiders as a show of confidence in the company's value-building strategy.
The PIPE was executed at a price of $5.04 per share, closing on January 26, 2026. Investors will partake in an 80% warrant coverage and adhere to a 180-day lock-up period, reflecting a commitment to the company's long-term vision. The funds raised will facilitate Cingulate's operations while it works toward a vital milestone: obtaining FDA approval for its lead candidate, CTx-1301, which utilizes the proprietary Precision Timed Release™ (PTR™) platform to deliver multiple doses of dexmethylphenidate throughout the day.
In conjunction with the financing, Falcon Creek Capital gains the right to appoint two board members, with former Cingulate member Jeff Hargroves taking the first seat. Hargroves brings extensive industry experience to the board.
Cingulate aims to launch CTx-1301, pending FDA approval, as part of a broader strategy to address the significant unmet needs for ADHD treatment among the 20 million affected individuals in the U.S. The anticipated PDUFA date for the new drug application is May 31, 2026, making this financing crucial for the company's growth and future prospects.
MWN-AI** Analysis
Cingulate Inc. (NASDAQ: CING) recently announced the successful closure of a $12 million private investment in public equity (PIPE) financing, reflecting strong institutional confidence in its strategic direction and product pipeline, particularly with the anticipated FDA approval of CTx-1301 for ADHD. Priced at $5.04 per share, the transaction included 80% warrant coverage, which may incentivize investor support and enhance liquidity in the future. The current market environment appears conducive to such financing, suggesting a positive sentiment toward biopharmaceutical companies with innovative products and a solid business strategy.
Investors should closely monitor upcoming milestones, including the May 31, 2026 PDUFA action date for CTx-1301. Success in this area could significantly impact Cingulate's market capitalization, especially as ADHD affects a substantial patient base in the U.S., presenting a lucrative commercial opportunity. The leadership change, with the inclusion of experienced director Jeff Hargroves from Falcon Creek Capital, may bring additional strategic insights and governance strength.
Cingulate’s share price volatility post-financing offers a potential entry point for investors. Given the 180-day lock-up for PIPE investors, short-term trading may be subdued, providing a window for longer-term investors to accumulate shares amid a potentially favorable approval landscape. However, prospective investors should remain cautious and aware of inherent risks outlined in Cingulate’s SEC filings, especially concerning regulatory timelines and market competition.
In conclusion, Cingulate stands at a pivotal juncture with strong institutional backing and a promising drug candidate. While caution is warranted, the potential upside linked to successful product commercialization presents an intriguing investment opportunity for those interested in biopharmaceutical sector growth.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
KANSAS CITY, Kan., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation treatments for ADHD and other CNS disorders, today announced the successful closing of a $12 million private investment in public equity (PIPE) financing, led by certain affiliates of Falcon Creek Capital Advisor LLC (“Falcon Creek Capital”).
“This long-term financing from life science–focused institutional investors represents strong validation of our strategy, our technology, and the significant commercial opportunity ahead. The transaction included insider participation underscoring our confidence in the value we are building and our commitment to standing shoulder-to-shoulder with our shareholders,” said Cingulate CEO Shane J. Schaffer. “The at-the-market pricing, six-month investor lock-up, and 80% warrant coverage reflect a well-structured transaction and compare favorably with current market conditions.”
The PIPE was completed at the closing price of $5.04 per share on January 26, 2026 with 80% warrant coverage.
All investors participating in the PIPE financing have agreed to a 180-day lock-up period, further aligning long-term investor interests and reinforcing confidence in the Company’s execution through key upcoming milestones.
The financing proceeds will support general operations as the company works toward a critical milestone—the commercial launch of CTx-1301, subject to FDA approval. In connection with the PIPE financing, Falcon Creek Capital received the right to designate up to two members of Cingulate’s board of directors, the first of which will be former Cingulate board member, Jeff Hargroves. Mr. Hargroves brings extensive pharmaceutical experience and a strong understanding of Cingulate’s strategic priorities and operations. Mr. Hargroves was also a significant participant in the PIPE financing.
The securities were issued in a private placement under Section 4(a)(2) of the Securities Act of 1933 and Regulation D and have not been registered under the Securities Act or applicable state securities laws. The Company has agreed to file a resale registration statement covering the shares issued and issuable in the transaction. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.
Transaction Summary
- PIPE Size: $12 million gross proceeds
- All investors in the PIPE financing are subject to a 180-day lock-up period pursuant to the definitive transaction documents
- Total Potential Proceeds: Up to $21.4 million
- Pricing: Nasdaq closing price on January 26, 2026 of $5.04 per share
- Preferred Stock: Convertible upon stockholder approval; accrues 12% annualized interest until conversion
- Warrants: Exercisable upon stockholder approval; three-year term.
About ADHD
Attention-Deficit/Hyperactivity Disorder (ADHD) is a chronic neurodevelopmental condition affecting approximately 20 million individuals in the United States, including 8 million children and 12 million adults. While stimulant medications remain the standard of care, existing extended-release products fail to provide consistent, entire active-day symptom control, often requiring multiple doses.
About CTx-1301
CTx-1301 is a once-daily, multi-core tablet utilizing Cingulate’s proprietary Precision Timed Release™ (PTR™) platform to deliver three precisely timed releases of dexmethylphenidate across the day. The candidate is being evaluated under the FDA’s 505(b)(2) regulatory pathway for the treatment of ADHD.
In October 2025, the FDA accepted Cingulate’s NDA for review and assigned a PDUFA target action date of May 31, 2026. NDA acceptance indicates that the submission is sufficiently complete for substantive review and does not imply approval or guarantee any specific outcome.
About Cingulate Inc.
Cingulate Inc. (NASDAQ: CING) is a biopharmaceutical company leveraging its proprietary Precision Timed Release™ (PTR™) platform to develop next-generation pharmaceutical products designed to improve outcomes in conditions marked by suboptimal therapeutic coverage and burdensome dosing schedules. The Company’s lead candidate, CTx-1301, is in commercial-stage development for ADHD, with additional pipeline programs targeting anxiety and other neuropsychiatric indications. Cingulate is headquartered in Kansas City, Kansas.
About Falcon Creek Capital
Falcon Creek Capital Advisor LLC is a specialized investment firm focused on public and private equity investments in the life sciences, healthcare, and technology sectors. The firm is known for its disciplined, long-term investment approach and for partnering with companies at pivotal inflection points, providing structured capital solutions that support commercialization, growth initiatives, and pipeline expansion. Falcon Creek Capital combines public market expertise with an active, collaborative approach to governance and strategic execution.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include all statements, other than statements of historical fact, regarding our current views and assumptions with respect to future events regarding our business, including statements with respect to our plans, assumptions, expectations, beliefs and objectives with respect to product development, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth opportunities and other statements that are predictive in nature. Specifically, these statements include, but are not limited to, statements regarding our expected cash runway, the potential approval and commercialization of CTx-1301, the potential PDUFA date of May 31, 2026, anticipated capital needs and financing plans, designation of Frederick Jiang as a board observer, and subject to stockholder approval, as a director, the long-term investment strategy of Falcon Creek and potential proceeds from the exercise of warrants. These statements are generally identified by the use of such words as “may,” “could,” “should,” “would,” “believe,” “anticipate,” “forecast,” “estimate,” “expect,” “intend,” “plan,” “continue,” “outlook,” “will,” “potential” and similar statements of a future or forward-looking nature. Readers are cautioned that any forward-looking information provided by us or on our behalf is not a guarantee of future performance. Actual results may differ materially from those contained in these forward-looking statements as a result of various factors disclosed in our filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” section of our Annual Report on Form 10-K filed with the SEC on March 27, 2025 and our other filings with the SEC. All forward-looking statements speak only as of the date on which they are made, and we undertake no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.
Investor & Media Relations:
Thomas Dalton
Vice President, Corporate and Government Relations, Cingulate
[email protected]
(480) 529-5434
FAQ**
How does Cingulate Inc.'s PIPE financing impact the pricing and future trading of Cingulate Inc. Warrants CINGW, especially considering the 80% warrant coverage included in the transaction?
What are the key milestones Cingulate Inc. is targeting ahead of the potential commercial launch of CTx-1301 that could influence the value of Cingulate Inc. Warrants CINGW?
Given the insider participation in the PIPE financing, how might this affect investor confidence and market perceptions of Cingulate Inc. Warrants CINGW moving forward?
How does the strategic involvement of Falcon Creek Capital potentially enhance the execution of Cingulate Inc.'s plans, particularly concerning the value of Cingulate Inc. Warrants CINGW?
**MWN-AI FAQ is based on asking OpenAI questions about Cingulate Inc. Warrants (NASDAQ: CINGW).
NASDAQ: CINGW
CINGW Trading
-9.91% G/L:
$0.0391 Last:
54,777 Volume:
$0.05 Open:
